Evidence map›Paper›PMID 40069204›Full record

ArticleNPJ breast cancer2025

Dynamic HER2-low status among patients with triple negative breast cancer (TNBC) and the impact of repeat biopsies.

Yael Bar, Geoffrey Fell, Aylin Dedeoglu, Natalie Moffett, Neelima Vidula, Laura Spring, Seth A Wander, Aditya Bardia, Naomi Ko, Beverly Moy and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ breast cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Cost and Cost-Effectiveness of Treating Human Epidermal Growth Factor Receptor 2-Low Metastatic Breast Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yael BarMassachusetts General Hospital Cancer Center, Boston, MA, USA. yael.b@tlvmc.gov.il.
Geoffrey FellMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Aylin DedeogluMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Natalie MoffettMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Neelima VidulaMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Laura SpringMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Seth A WanderMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Aditya BardiaMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Naomi KoSection of Hematology/Oncology, Department of Medicine, Boston University School of Medicine, Boston, MA, USA.
Beverly MoyMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Leif W EllisenMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Steven J IsakoffMassachusetts General Hospital Cancer Center, Boston, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Trastuzumab deruxtecan (T-DXd) is approved for HER2-low (HER2 immunohistochemistry (IHC)1+ or 2+ with non-amplified in situ hybridization (ISH)), but not HER2-0 (IHC 0) metastatic breast cancer. The impact of repeat biopsies (Bxs) in identifying new potential candidates with triple negative breast cancer (TNBC) for T-DXd treatment remains unknown. 512 consecutive patients with TNBC at diagnosis were included in the study cohort. Bxs were categorized as core, surgical, or metastatic based on the timing and method of biopsy (Bx) acquisition, and the total number of Bxs was determined for each patient. Additionally, matched biopsies were identified, and the rate of discordance in HER2 status was calculated. The proportion of patients with at least one HER2-low result increased as the number of successive Bxs increased [59%, 73%, 83%, 83%, and 100% when 1 (196 patients), 2 (231 patients), 3 (48 patients), 4 (29 patients), and ≥ 5 (8 patients) Bxs were obtained, respectively]. Among patients without a prior HER2-low result, approximately one-third demonstrated HER2-low status with each additional successive Bx. HER2 status exhibited variability between matched Bxs, with observed discordance rates of 26%, 44%, and 33% between matched core-surgical, early-metastatic, and two metastatic matched Bxs, respectively. Our findings indicate that HER2 status can vary between different Bxs taken during the disease course of patients with TNBC with the highest discordance rate observed between the primary and metastatic Bxs. For patients with metastastic HER2-0 TNBC, repeat Bxs can increase the chance of obtaining a HER2-low result, thereby offering patients a promising therapeutic option.

Identifiers

PMID40069204
PMCPMC11897376

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.